How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

bleeding has diabetes has strong family history of breast cancer (defined as one or more first degree relatives, breast cancer occurring before menopause in three or more family members, regardless of degree of relationship, and any male family member with breast cancer), or current or history of breast cancer, or undiagnosed mass detected by breast exam has current or history of cervical cancer has severe cirrhosis (decompensated) or liver tumors has known significant renal disease used Depo-Provera (...) Contraceptive Injection or Depo-subcutaneous Provera 104 (DMPA) products in the past 12 months used any of the following medications within 1 month prior to enrollment: any investigational drug prohibited drugs per protocol oral contraceptives, contraceptive ring or patch levonorgestrel intrauterine system (LNG IUS) or contraceptive implant used a combined injectable contraceptive in the past 6 months less than 3 months since the end of last pregnancy currently lactating is using or plans to use prohibited

2016 Clinical Trials

262. Pathophysiology of Paget's Disease of Bone

NOT have evidence of Paget's disease of bone as defined by: No bone pain or bony deformity Normal serum alkaline phosphatase Exclusion Criteria: Osteosarcoma or other blastic bony metastases alone Fibrous dysplasia of bone Hyperostosis frontalis interna All men and women < 18 years or > 99 years Pregnancy (women) determined by self-report Current use of oral contraceptive tablets or Depo-Provera™ (women) Current use of hormone replacement therapy Creatinine clearance < 60 ml/min./1.73 m2 by Cockcroft

2016 Clinical Trials

263. Contraceptive Practices of Women With Complex Congenital Heart Disease. (Abstract)

) 84%, intrauterine device (18%), Depo-Provera (15%), vaginal ring (7%), patch (6%), hormonal implant (2%), Plan B (19%), and sterilization (16%). Overall OC use was not significantly different by CHD complexity. Women with CHD of great complexity were more likely to report a thrombotic event while taking OC than those with less complex CHD (9% vs 1%, p = 0.003). Contraception counseling by the ACHD team was noted by 43% of subjects. Unplanned pregnancy was reported by 25% with no statistical

2016 American Journal of Cardiology

264. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review. (Abstract)

to contraceptive type.Of 3597 articles retrieved, 9 studies met criteria for SR. Synthesized across studies, 12-month continuation was significantly higher for IUD users (86.5%, 12,761/14,747) compared with oral contraceptives (39.6%, 1931/4873), Depo-Provera (Pfizer Inc, New York, NY) hormonal injection (39.8%, 510/1282), vaginal ring (48.9%, 196/401), and transdermal patch (39.8%, 37/93; all P values < .001). There was no statistically significant difference in 12-month continuation between the IUD

2016 Journal of pediatric and adolescent gynecology

265. Who has a repeat abortion? Identifying women at risk of repeated terminations of pregnancy: analysis of routinely collected health care data. (Full text)

termination. In those who had repeat terminations, women who had an implant or Depo-Provera(®) were at increased odds of repeat termination in the 2-5 years interval compared to the 0-2 years after their initial termination.Teenage pregnancy, social deprivation, two or more previous livebirths or miscarriages at the time of the initial termination were identified as risk factors for repeat terminations. Post-termination contraception with implants and Depo-Provera® were associated with repeat termination

2015 Journal of Family Planning and Reproductive Health Care PubMed abstract

266. Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

of birth control throughout the study and for 7 days immediately after the last dose of study drug. Medically acceptable methods of birth control include bilateral tubal ligation or the use of either a contraceptive implant, a contraceptive injection (e.g., Depo Provera™), an intrauterine device, or an oral contraceptive taken continually within the past three months and which the subject agrees to continue using during the study or to adopt another birth control method, or a double-barrier method

2015 Clinical Trials

267. PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB

becomes even more important because it allows women to attain a level of health that will support healthy future pregnancies. Treatment options for TB may be limited in pregnancy because of concerns about teratogenicity. Millions of women around the world use depot medroxyprogesterone acetate (DMPA, trade name Depo-Provera) for prevention of pregnancy. DMPA is an intermediate-acting progesterone-only injectable contraceptive with a high efficacy rate. Unfortunately, DMPA's safety and effectiveness

2015 Clinical Trials

268. An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation

(Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method (condoms with spermicide or diaphragm with spermicide) Non-hormonal intrauterine devices Vasectomy of partner Non-heterosexual lifestyle Subjects must have at least two of the following criteria based on subject self-reporting, for the past 3 months with the symptoms beginning at least 6 months ago: Two or more criteria must be met

2015 Clinical Trials

269. Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol

for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. Active infection including hepatitis B, hepatitis C, HIV, or TB. A positive skin test (PPD) in itself

2015 Clinical Trials

270. An Open-label Phase II Study of Lorvotuzumab Mertansine

forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation. Male patients with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, during the study. Females must be surgically or biologically sterile or postmenopausal

2015 Clinical Trials

271. A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands

of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and/or vasectomies of partner with a documented second acceptable method of birth control, should the subject become sexually active. Negative urine pregnancy test results at the time

2015 Clinical Trials

272. Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

and Science University Asociación Dominicana Pro Bienestar de la Familia, Inc. Information provided by (Responsible Party): FHI 360 Study Details Study Description Go to Brief Summary: This is a randomized, multi-center, parallel-group Phase I study to evaluate the pharmacodynamics (PD) of Medroxyprogesterone Acetate (MPA) after a single subcutaneous (SC) injection of 150 mg/mL or 300 mg/2 mL Depo-Provera CI in the abdomen of women of reproductive age with a confirmed ovulatory baseline cycle. Condition (...) or disease Intervention/treatment Phase Contraception Drug: DMPA 150 Drug: DMPA 300 Drug: DMPA 104 Phase 1 Detailed Description: This is a randomized, multi-center, parallel-group Phase I study with a primary objective to evaluate the pharmacodynamics (PD) of Medroxyprogesterone Acetate (MPA) after a single subcutaneous (SC) injection of 150mg/mL or 300mg/2mL Depo-Provera CI in the abdomen of women of reproductive age with a confirmed ovulatory baseline cycle. Secondary study objectives are: To evaluate

2015 Clinical Trials

273. A Safety Study Of The Caya® Diaphragm Used With ContraGel®

. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome. Current use of any hormonal contraceptive (oral, transdermal, transvaginal, implant, or hormonal intrauterine contraceptive device) or a copper intrauterine device (IUD), or use of Depo-Provera in the last 6 months Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study Significant gynecological abnormalities (including

2015 Clinical Trials

274. Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. Presence or history of active infection including hepatitis B, hepatitis C

2015 Clinical Trials

275. An Open Label Study Evaluating the Effectiveness of Omega Q Plus® Resveratrol at Increasing Blood Levels of CoQ10

contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System). Double-barrier method. Non-hormonal intrauterine devices. Vasectomy of partner. Non-heterosexual lifestyle (same-sex relationship). CoQ10 levels between 0.5 mcg/mL - 1 mcg/mL Agree to maintain current level of physical activity, caffeine consumption habits, alcohol consumption habits, smoking habits and dietary habits (...) last menstruation). OR Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System). Double-barrier method. Non-hormonal intrauterine devices

2015 Clinical Trials

276. A Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation

(Depo-Provera, Lunelle), or hormone implant (Norplant System)), Intrauterine devices, Vasectomy of partner, Non-heterosexual lifestyle BMI 18.5-35.0kg/m2 Subjects must have < 3 bowel movements per week for at least 2 weeks (but for not more than 12 weeks in the past 6 months) prior to randomization (confirmed at screening and baseline) and the presence of at least one other bowel symptom of constipation in at least 25% of defecations; Hard stools. or complete lack of loose or watery stools

2015 Clinical Trials

277. Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients

) surgical sterilization, such as hysterectomy, tubal ligation or vasectomy. (2) approved hormonal contraceptives, such as birth control pills, patch or ring; Depo-Provera, Implanon. (3) barrier methods, such as condom, cervical cap or diaphragm used with a spermicide. (4) an intrauterine device (IUD). Exclusion Criteria: Laboratory or other histologic findings highly suggestive of liver disease due to causes other than non-alcoholic steatohepatitis, such as chronic viral hepatitis, autoimmune hepatitis

2015 Clinical Trials

278. Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B

, be capable of preventing pregnancy for at least one month prior to determination of eligibility (to include abstinence or contraceptives (for example intrauterine contraceptive device; oral contraceptives; Norplant® or Depo-Provera® ), and must agree to continue such precautions for two months after completion of the vaccination series. Written informed consent must be obtained from the subject before screening procedures. Exclusion Criteria: • Prior receipt of any investigational malaria vaccine Prior

2015 Clinical Trials

279. Dual Protection Project

medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera

2015 Clinical Trials

280. Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

: This criterion is not applicable to participants who report using a progestin-only method of contraception at screening (e.g., Depo-Provera or levonorgestrel-releasing IUD) nor to participants using continuous combination oral contraceptive pills, as the absence of regular menstrual cycles is an expected, normal consequence in this context. At screening, participant states a willingness to refrain from inserting any non-study vaginal products or objects into the vagina, including but not limited

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>